Table 1 Clinical characteristics of the patients with SMH secondary to neovascular AMD.

From: Intravitreal anti-vascular endothelial growth factor monotherapy in age-related macular degeneration with submacular hemorrhage

Number of patients

62

Number of eyes (right/left)

62 (25/37)

Age, mean ± SD, year

75.0 ± 9.8

Sex (male/female) (%)

45(73)/17 (27)

Anti-VEGF, aflibercept/brolucizumab (%)

46(74)/16(26)

The subtype of AMD (PCV/non-PCV) (%)

39(63)/23 (37)

Anticoagulant medication (+ /−) (%)

6(10)/56(90)

Duration of symptoms (days)

27.4 ± 20.9 (range, 2–90)

Mean size of submacular hemorrhage (DAs)

3.0 ± 2.0 (range, 1–11)

Vitreous hemorrhage during treatment, n (%)

5(8.1)

Mean baseline logMAR BCVA

0.43 ± 0.36

Mean number of anti-VEGF injections

6.0 ± 2.3 (range, 1–12)

Mean central foveal thickness (µm)

567 ± 245

Mean thickness of SMH at the fovea (µm)

214 ± 167

Mean thickness of hemorrhagic PED at the fovea (µm)

201 ± 253

  1. SMH submacular hemorrhage, AMD age-related macular degeneration, SD standard deviation, VEGF vascular endothelial growth factor, PCV polypoidal choroidal vasculopathy, DAs disc areas, BCVA best-corrected visual acuity, PED pigment epithelial detachment.
Back to article page